Mesabi Trust

Mesabi Trust

Yahoo Finance • 17 hours ago

Cochlear And 2 Australian Healthcare Stocks To Watch

Australian inflation accelerated to 4% in August, and interest rates now sit at a 15 year high of 4.6%. That mix is putting cost pressure on households while lifting the appeal of resilient sectors. Healthcare often holds up when budgets t... Full story

Yahoo Finance • last month

PDI Gold Stock Leads These Fast Growing Insider Backed Commodity Picks

Global debt markets are back in focus as the US 10 year yield hovers around the mid 4% range ahead of Jackson Hole. Higher yields can punish weaker balance sheets, yet they often highlight companies that still commit their own capital. Thi... Full story

Yahoo Finance • 2 months ago

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain Activity Report for Quarter Ended Ju... Full story

Yahoo Finance • 3 months ago

Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Application (BLA) fi... Full story

Yahoo Finance • 5 months ago

Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB)... Full story

Yahoo Finance • 5 months ago

ASX Penny Stocks To Watch In April 2026

As the Australian market faces its seventh consecutive day in the red, with inflation expected to spike to nearly three-year highs, investor sentiment has turned bearish. Despite these challenging conditions, penny stocks remain a relevant... Full story

Yahoo Finance • 5 months ago

Assessing Mesoblast’s Valuation After Recent Share Price Weakness And Conflicting Growth Signals

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Mesoblast share move and recent return profile Mesoblast (ASX:MSB) recently closed at A$2.15, catching attention afte... Full story

Yahoo Finance • 6 months ago

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a pat... Full story

Yahoo Finance • 6 months ago

PureCycle leads short interest in small-cap materials stocks through March

[Trading charts background] da-kuk Rising geopolitical tensions are putting short interest in materials stocks back in the spotlight, highlighting investor caution around steel, chemicals, and metals firms exposed to trade and supply chai... Full story

Yahoo Finance • 6 months ago

Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter

Strong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medic... Full story

Yahoo Finance • 7 months ago

Mesoblast to Host R&D Day on April 8, 2026

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City... Full story

Yahoo Finance • 8 months ago

Top small-cap materials stocks surging above 200-Day moving average

[Small Cap write on sticky notes isolated on Office Desk. Stock market concept] syahrir maulana/iStock via Getty Images Year to date in 2026, U.S. smallcap stocks represented by the iShares Core S&P Small-Cap ETF (IJR [https://seekingalph... Full story

Yahoo Finance • 10 months ago

Mesoblast Participation at Piper Sandler Conference

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler 37th Annual Healthcare... Full story

Yahoo Finance • 11 months ago

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

NEW YORK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the first quarter ende... Full story

Yahoo Finance • 12 months ago

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$21.9 million on Ryoncil® (remestemcel-L-r... Full story

Yahoo Finance • 12 months ago

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a specific Healthcare Common Procedure Coding System (HC... Full story

Yahoo Finance • last year

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured... Full story

Yahoo Finance • last year

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil® (remestemcel-L-r... Full story

Yahoo Finance • last year

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements... Full story

Yahoo Finance • last year

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period end... Full story